Targeting resistant cells in lung cancer treatment
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)
This study is looking at why some lung cancer cells don't respond to certain treatments and aims to find new ways to help patients get better by targeting those stubborn cells, which could lead to longer-lasting results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10926884 on NIH RePORTER |
What this research studies
This research focuses on understanding and overcoming resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). It investigates the mechanisms behind drug-tolerant persister cells that survive initial treatments and may lead to cancer progression. The approach includes identifying novel targets and developing new drug combinations to effectively eliminate these resistant cells. Patients may benefit from improved treatment strategies that could enhance their chances of long-term remission.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer who have mutations in the EGFR gene and have experienced resistance to current TKI therapies.
Not a fit: Patients with lung cancer who do not have EGFR mutations or who are not currently undergoing TKI treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by overcoming drug resistance.
How similar studies have performed: Previous research has shown promise in targeting drug-resistant cancer cells, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Nilsson, Monique B — University of Tx Md Anderson Can Ctr
- Study coordinator: Nilsson, Monique B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.